Granules Pharmaceuticals, Inc. Receives USFDA EIR for Chantilly Facility

Granules India Limited today announced that its wholly-owned subsidiary, Granules Pharmaceuticals, Inc. (GPI), located in Chantilly, Virginia, US, has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA), with a Voluntary Action Indicated (VAI) classification.

The inspection was conducted from March 30 to April 3, 2026, during which four Form 483 observations were issued.

This facility plays an important role in Granules' global manufacturing and supply network, with a continued focus on quality systems, regulatory compliance, and patient safety.

Granules remains committed to maintaining the highest standards of quality, safety, and regulatory compliance across its facilities in India and the US.

Shares of Granules India Limited was last trading in BSE at Rs. 792.95 as compared to the previous close of Rs. 776.85. The total number of shares traded during the day was 521227 in over 2210 trades.

The stock hit an intraday high of Rs. 795.70 and intraday low of 779.95. The net turnover during the day was Rs. 406856391.00.

Source : Equity Bulls

Keywords

GranulesIndia INE101D01020 GRANULESPharmaceuticals EIR USFDA